{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:15:32Z","timestamp":1760660132443,"version":"build-2065373602"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejim.2022.05.013","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T08:10:27Z","timestamp":1652688627000},"page":"88-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Impact of cardiac amyloidosis on outcomes of patients hospitalized with heart failure"],"prefix":"10.1016","volume":"102","author":[{"given":"Sebastian","family":"G\u00f6bel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Hobohm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Desuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"M\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapezzi","family":"Claudio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ejim.2022.05.013_bib0001","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/archinte.166.17.1805","article-title":"Amyloidosis and the heart: a comprehensive review","volume":"166","author":"Shah","year":"2006","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.ejim.2022.05.013_bib0002","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.carpath.2006.01.005","article-title":"Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy","volume":"15","author":"Steiner","year":"2006","journal-title":"Cardiovasc Pathol"},{"issue":"4","key":"10.1016\/j.ejim.2022.05.013_bib0003","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.carpath.2009.04.005","article-title":"High prevalence of amyloid in 150 surgically removed heart valves\u2013a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions","volume":"19","author":"Kristen","year":"2010","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.ejim.2022.05.013_bib0004","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejim.2022.05.013_bib0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ejim.2022.05.013_bib0006","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS)","volume":"43","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ejim.2022.05.013_bib0007","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"Light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ejim.2022.05.013_bib0008","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"38","key":"10.1016\/j.ejim.2022.05.013_bib0009","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.ejim.2022.05.013_bib0010","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejim.2022.05.013_bib0011","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: position statement of the German cardiac society (DGK)","volume":"110","author":"Yilmaz","year":"2021","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"10.1016\/j.ejim.2022.05.013_bib0012","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejim.2022.05.013_bib0013","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the amyloidosis research consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.ejim.2022.05.013_bib0014","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.ejim.2022.05.013_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ejim.2022.05.013_bib0016","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejim.2022.05.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"7","key":"10.1016\/j.ejim.2022.05.013_bib0018","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2022.05.013_bib0019","unstructured":"Internet Page of the InEK GmbH, Institut f\u00fcr das Entgeltsystem im Krankenhaus vanO. Deutsche kodierrichtlinien 2018 druckversion A4 (PDF). https:\/\/www.g-drg.de\/inek_site_de\/layout\/set\/standard\/Media\/Files\/G-DRG-System\/G-DRG-System_2018\/Deutsche_Kodierrichtlinien_2018_Druckversion_A4_PDF 2018 (assessed 10th April 2019)."},{"issue":"5","key":"10.1016\/j.ejim.2022.05.013_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"12","key":"10.1016\/j.ejim.2022.05.013_bib0021","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCRESAHA.117.310643","article-title":"Amyloid cardiomyopathy: disease on the rise","volume":"120","author":"Liao","year":"2017","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.ejim.2022.05.013_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.ejim.2022.05.013_bib0023","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ejim.2022.05.013_bib0024","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10554-016-0915-z","article-title":"Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy","volume":"32","author":"Bennani Smires","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.ejim.2022.05.013_bib0025","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ejim.2022.05.013_bib0026","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement","volume":"71","author":"Scully","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2022.05.013_bib0027","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in Olmsted county, Minnesota, 1990 through 2015","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.ejim.2022.05.013_bib0028","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.ejim.2022.05.013_bib0029","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.ejim.2022.05.013_bib0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification international society of amyloidosis 2016 nomenclature guidelines","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"issue":"24","key":"10.1016\/j.ejim.2022.05.013_bib0031","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ejim.2022.05.013_bib0032","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2022.05.013_bib0033","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/annonc\/mdt544","article-title":"Cancer risk in amyloidosis patients in Sweden with novel findings on non-Hodgkin lymphoma and skin cancer","volume":"25","author":"Hemminki","year":"2014","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ejim.2022.05.013_bib0034","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejim.2022.05.013_bib0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive review of AL amyloidosis: some practical recommendations","volume":"11","author":"Al Hamed","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.ejim.2022.05.013_bib0036","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"Current chemotherapy and immune therapy treatment strategies: JACC: cardiooncology state-of-the-art review","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ejim.2022.05.013_bib0037","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac amyloidosis: overlooked, underappreciated, and treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu Rev Med"},{"issue":"8","key":"10.1016\/j.ejim.2022.05.013_bib0038","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"17","key":"10.1016\/j.ejim.2022.05.013_bib0039","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2022.05.013_bib0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"issue":"19","key":"10.1016\/j.ejim.2022.05.013_bib0041","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1056\/NEJM197911083011907","article-title":"Factor X deficiency in primary amyloidosis: resolution after splenectomy","volume":"301","author":"Greipp","year":"1979","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejim.2022.05.013_bib0042","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V97.6.1885","article-title":"Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy","volume":"97","author":"Choufani","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejim.2022.05.013_bib0043","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pcad.2009.11.007","article-title":"Amyloid heart disease","volume":"52","author":"Falk","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"10.1016\/j.ejim.2022.05.013_bib0044","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/anec.12032","article-title":"Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis","volume":"18","author":"Boldrini","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"4","key":"10.1016\/j.ejim.2022.05.013_bib0045","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2004.10.028","article-title":"Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement","volume":"95","author":"Murtagh","year":"2005","journal-title":"Am J Cardiol"},{"issue":"13","key":"10.1016\/j.ejim.2022.05.013_bib0046","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ejim.2022.05.013_bib0047","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/2047487320936020","article-title":"Temporal trends and predictors of inhospital death in patients hospitalised for heart failure in Germany","volume":"28","author":"Keller","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"sup1","key":"10.1016\/j.ejim.2022.05.013_bib0048","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13506129.2016.1272453","article-title":"Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?","volume":"24","author":"Aus dem Siepen","year":"2017","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.ejim.2022.05.013_bib0049","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","article-title":"Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy","volume":"6","author":"Liu","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"19","key":"10.1016\/j.ejim.2022.05.013_bib0050","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"issue":"10","key":"10.1016\/j.ejim.2022.05.013_bib0051","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","article-title":"Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy","volume":"51","author":"Vogelsberg","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.ejim.2022.05.013_bib0052","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejim.2022.05.013_bib0053","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362052200190X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362052200190X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:37:03Z","timestamp":1760607423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362052200190X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":53,"alternative-id":["S095362052200190X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2022.05.013","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of cardiac amyloidosis on outcomes of patients hospitalized with heart failure","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2022.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}